GoldenGolden
Advanced Search
Becton Dickinson

Becton Dickinson

A medical technology company manufacturing and selling reagents, instrument systems, and medical devices.

Becton Dickinson is a medical technology company manufacturing and selling reagents, instrument systems, and medical devices that is headquartered in Franklin Lakes, New Jersey and was founded in 1897 by Fairleigh Dickinson and Maxwell Becton. The three worldwide business segments of BD are BD Medical, BD Diagnostics and BD Biosciences. BD Medical produces medical devices such as needles and syringes. BD Diagnostics provides products for safe collection and transport of diagnostics specimens, instruments and reagents. BD Biosciences produces research and clinical tools related to the analysis of cells including antibodies and diagnostic assays.

BD is the largest manufacturer of injection devices in the world. BD’s global manufacturing network produces billions of syringes and needles annually.

COVID-19 response

On March 17, 2020 Becton Dickinson submitted requests to the Food and Drug Administration (FDA) to approve their COVID-19 tests. Becton Dickinson partnered with the biotechnology company BioGX to develop the COVID-19 test, and seeks to use the tests in the United States under the Emergency Use Authorization act that allows for the expedited review of new tests under emergency situations like the COVID-19 pandemic. The company is also working on a faster test which they hope till produce test results for the COVID-19 virus in less than 10 minutes.

The CEO of Becton Dickinson, Tom Polen, made the following statement regarding his company's COVID-19 test:

I don’t think there will be tests that are any faster at this point than [two hours]. It’s a fully automated test so you snap in the test strip, put in the sample, close the door and press the button and the results come out in about two hours.

During the COVID-19 pandemic BD received orders from the US, Canada, the UK and across the world to supply needles and syringes, totaling 330 million as of July 2020, for administration of COVID-19 vaccines. Orders were set to be delivered by the end of 2020 in anticipation to be used for a vaccine expected to be approved late 2020 or early 2021. Expanded needle and syringe production at BD facilities in Nebraska are part of a public-private partnership with BARDA, the Office of the Assistant Secretary for Preparedness and Response (US Health and Human Services) and the Department Department of Defense's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND).

BD also produces swabs for COVID-19 testing, COVID-19 rapid molecular diagnostic tests that run on the BD MAX System and other products used in COVID-19 treatment such as infusion pumps, sets and catheters.

Funding
Initial public offering

On January 6, 2015 Becton Dickinson held their initial public offering (IPO) under the ticker SWX:BDX.

Post-ipo equity

On August 26, 2015 Becton Dickinson announced raising $15 million in post-ipo equity funding from Global health Investment Fund (GHIF).

Private equity round

On March 8, 2016 Becton Dickinson announced raising an undisclosed amount of private equity funding from Apax Partners that evaluated the company to be worth nearly $500 million. The private equity round sold 50.1% of of its respiratory solutions business to funds advised by Apax Partners to crate a joint venture operating as an independent company. A partner of Apax Partners, Steven Dyson, made the following statements about the deal:

We have been proactively targeting the industry for respiratory devices and have been impressed with the continued progress the company has made over the past few years. We are pleased to have the opportunity to work with the entire team in further developing Respiratory Solutions' position as a focused and leading global player. In order to take advantage of this opportunity, we are highly supportive of an investment program to further strengthen the business's existing platform, both organically and through acquisitions.

Timeline

May 25, 2021
BD announces the availability of BD SurgiphorTM Sterile Wound Irrigation System, the first and only ready-to-use aqueous povidone-iodine (PVP-I) irrigation solution that mechanically loosens and removes wound debris.
April 28, 2021
Becton Dickinson announces the appointment of Elizabeth McCombs as executive vice president and chief technology officer, succeeding John DeFord.
April 26, 2021
BD announces FDA 510(k) submission for BD AlarisTM System
February 2, 2021
BD announces that new clinical data have found robust evidence that using a vascular care solution can help improve outcomes for patients requiring peripheral intravenous catheters (PIVCs).
July 31, 2020
Becton Dickinson raises a $24,000,000 grant from U.S. Department of Defense.
August 26, 2015
Becton Dickinson raises a $15,000,000 venture round from Global Health Investment Fund.

Funding rounds

Acquisitions

People

Name
Role
LinkedIn

Aaron Shepard

Employee

Adam Hernandez

Employee

Adam Kalbermatten

Employee

Adithya Mohan Krishnaswamy

Employee

Adrien Malick

Employee

Akash Vashistha

Employee

Alan L Fisher

Employee

Alan Lance Evan Fisher

Employee

Albert M

Employee

Alec Alpert

Employee

Alec Wong

Employee

Alex Tieger

Employee

Alexander Canton

Employee

Alexander Chen

Employee

Alfonso R. Escobar Peñalver

Employee

Aline Bouhey-Abravanel

Employee

Alireza Salehi Borojerdi

Employee

Aliza Molgora

Employee

Allison Carleton

Employee

Amber Dubey

Employee

Amin Ronaghi

Employee

Amir Patel

Employee

Amish Rohatgi

Employee

Amit Tyagi

Employee

Andrea Kyeremeh

Employee

Page 1 of 17
...

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BD (Becton, Dickinson and Company)
June 11, 2021
www.prnewswire.com:443
/PRNewswire/ -- USA Swimming, the national governing body for the sport of swimming in the United States, and BD (Becton, Dickinson and Company) (NYSE: BDX), a...
BioSpace
June 2, 2021
BioSpace
BD, a leading global medical technology company, announced that it has become the first medical technology company authorized as a Common Vulnerability and Exposures Numbering Authority by the CVE Program, further demonstrating the company's leadership in health care cybersecurity.
BD (Becton, Dickinson and Company)
May 26, 2021
www.prnewswire.com:443
/PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the...
BD (Becton, Dickinson and Company)
May 25, 2021
www.prnewswire.com:443
/PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today the availability of BD SurgiphorTM...
BioSpace
May 19, 2021
BioSpace
Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral diseases, today announced the appointment of Tariq Arshad, MD, MBA to the newly-created position of Senior Vice President, Chief Medical Officer.
Conor Hale
May 13, 2021
FierceBiotech
To help catch more cases of cervical cancer and precancer before they can grow and spread, BD has secured a European approval for an at-home test for human papillomavirus, or HPV.
Research and Markets
May 10, 2021
www.prnewswire.com:443
/PRNewswire/ -- The "Disposable Syringes Market Size, Trends & Analysis, By Product Type, By Application, By End Use, And By Region, Global Forecast To 2028"...
Andrea Park
May 6, 2021
FierceBiotech
The new company will build on BD's established footprint in the diabetes care market, where it reported revenues of nearly $1.1 billion for the 2020 fiscal year.
BD (Becton, Dickinson and Company)
May 6, 2021
www.prnewswire.com:443
/PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.9 billion...
BD (Becton, Dickinson and Company)
April 29, 2021
www.prnewswire.com:443
/PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the...
April 29, 2021
BioSpace
BD Announces Enrollment in Post-Market Studies of the WavelinQTM Arteriovenous Endovascular Fistula - read this article along with other careers information, tips and advice on BioSpace
BD (Becton, Dickinson and Company)
April 29, 2021
www.prnewswire.com:443
/PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that enrollment has begun and the...
BioSpace
April 28, 2021
BioSpace
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of Elizabeth McCombs as executive vice president and chief technology officer, effective April 26, 2021
BD (Becton, Dickinson and Company)
April 28, 2021
www.prnewswire.com:443
/PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of Elizabeth...
BD (Becton, Dickinson and Company)
April 27, 2021
www.prnewswire.com:443
/PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.83 per common share, payable...
BD (Becton, Dickinson and Company)
April 27, 2021
www.prnewswire.com:443
/PRNewswire/ -- CerTest Biotec, along with BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the...
BD (Becton, Dickinson and Company)
April 26, 2021
www.prnewswire.com:443
/PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has submitted a 510(k)...
BD (Becton, Dickinson and Company); USA Track & Field
April 23, 2021
www.prnewswire.com:443
/PRNewswire/ -- USA Track & Field (USATF) and BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, have partnered to...
BD (Becton, Dickinson and Company)
April 20, 2021
www.prnewswire.com:443
/PRNewswire/ -- BD (Becton, Dickinson and Company), a leading global medical technology company, is voluntarily recalling specified lots of the ChloraPrepTM...
BD (Becton, Dickinson and Company)
April 14, 2021
www.prnewswire.com:443
/PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received 510(k) clearance...
SHOW MORE

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.